# Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

> **NCT07492342** · PHASE2 · RECRUITING · sponsor: **Jianxing He** · enrollment: 30 (estimated)

## Conditions studied

- Resectable NSCLC
- KRAS G12C Mutation
- Stage IB-IIIA NSCLC
- Neoadjuvant Therapy

## Interventions

- **DRUG:** fulzerasib

## Key facts

- **NCT ID:** NCT07492342
- **Lead sponsor:** Jianxing He
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492342, "Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07492342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*